Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III
Biopharmaceutical Report I Issue18_December 2018 Aldeyra Therapeutics’ (NASDAQ:ALDX) focus on seasonal allergies in its Phase III study...